LUNAR-COV19, is a COVID-19 vaccine candidate developed by which organization?

Question

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
Arcturus Therapeutics has partnered with Singapore's Duke–NUS Medical School to develop this COVID-19 vaccine.
The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.
LUNAR-COV19 clinical trials in humans began in 2020.
In 2021, Arcturus Therapeutics started Phase-2 clinical trials.
Arcturus has signed a development and supply agreement with the Economic Development Board of Singapore and a supply agreement with the Israeli Ministry of Health for LUNAR-COV19.

GKToday Admin · Accepted Answer

Arcturus Therapeutics

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
Arcturus Therapeutics has partnered with Singapore's Duke–NUS Medical School to develop this COVID-19 vaccine.
The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.
LUNAR-COV19 clinical trials in humans began in 2020.
In 2021, Arcturus Therapeutics started Phase-2 clinical trials.
Arcturus has signed a development and supply agreement with the Economic Development Board of Singapore and a supply agreement with the Israeli Ministry of Health for LUNAR-COV19.

Current Affairs